Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.87 |
| ▸ | CHAT | P28329 | 2/20 | 0.83 |
| ▸ | EP300 | Q09472 | 3/20 | 0.82 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.82 |
| ▸ | AURKA | O14965 | 2/20 | 0.82 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.82 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2757454 | 1.00 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL849827 | 1.00 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL27830848 | 1.00 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| Hexanoyl-Coa SCHEMBL21496009 | 0.98 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| Hexanoyl-Coa SCHEMBL60392 | 0.98 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| Hexanoyl-Coa SCHEMBL11940278 | 0.98 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| Octanoyl-Coa SCHEMBL24667663 | 0.98 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL1129961 | 0.98 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| Dodecanoyl-Coa SCHEMBL4309283 | 0.98 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL20970006 | 0.98 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713320-A2 | BCAT2 INHIBITORS | Agios Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4638753-A2 | PRODUCTION OF CANNABINOIDS AND ENGINEERED CELLS THEREFOR | Cellibre, Inc. (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4565706-A1 | MICROBIAL PRODUCTION OF MONOMERS FOR RECYCLING OF PLASTIC POLYMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-06-11 | — | — | EP | claimed |
| WO-2024030662-A9 | MICROBIAL PRODUCTION OF MONOMERS FOR RECYCLING OF PLASTIC POLYMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-27 | — | — | WO | claimed |
| WO-2024238820-A2 | BCAT2 INHIBITORS | AGIOS PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | WO | claimed |
| EP-4430036-A2 | BCAT2 INHIBITORS | Agios Pharmaceuticals, Inc. (US) | 2024-09-18 | — | — | EP | claimed |
| WO-2024138205-A2 | PRODUCTION OF CANNABINOIDS AND ENGINEERED CELLS THEREFOR | CELLIBRE, INC. (US) | 2024-06-27 | — | — | WO | claimed |
| US-20240052332-A1 | OLIVETOLIC ACID CYCLASE VARIANTS AND METHODS FOR THEIR USE | CREO INGREDIENTS, INC. | 2024-02-15 | — | — | US | claimed |
| WO-2024030662-A1 | MICROBIAL PRODUCTION OF MONOMERS FOR RECYCLING OF PLASTIC POLYMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-08 | — | — | WO | claimed |
| EP-4305173-A1 | RECOMBINANT MICROORGANISMS AND USES THEREFOR | Lanzatech, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| EP-4103679-A1 | PREPARING AND MODIFYING MEROTERPENE POLYKETIDES, KETONES, AND LACTONES FOR CANNABINOID SEMISYNTHESIS | Lygos, Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| US-20220315969-A1 | OLIVETOLIC ACID CYCLASE VARIANTS AND METHODS FOR THEIR USE | CREO INGREDIENTS, INC. | 2022-10-06 | — | — | US | claimed |
| WO-2022192865-A1 | RECOMBINANT MICROORGANISMS AND USES THEREFOR | LANZATECH, INC. (US) | 2022-09-15 | — | — | WO | claimed |
| US-20220282289-A1 | RECOMBINANT MICROORGANISMS AND USES THEREFOR | UNITED STATES DEPARTMENT OF ENERGY | 2022-09-08 | — | — | US | claimed |
| US-20220274967-A1 | BCAT MODULATION | ICAGEN, LLC | 2022-09-01 | — | — | US | claimed |
| WO-2022125645-A1 | OLIVETOLIC ACID CYCLASE VARIANTS AND METHODS FOR THEIR USE | GENOMATICA, INC. (US) | 2022-06-16 | — | — | WO | claimed |
| US-20220177858-A1 | OLIVETOL SYNTHASE VARIANTS AND METHODS FOR PRODUCTION OF OLIVETOLIC ACID AND ITS ANALOG COMPOUNDS | CREO INGREDIENTS, INC. | 2022-06-09 | — | — | US | claimed |
| EP-3997080-A1 | BCAT MODULATION | Icagen, LLC (US) | 2022-05-18 | — | — | EP | claimed |
| EP-3980520-A1 | OLIVETOLIC ACID CYCLASE VARIANTS AND METHODS FOR THEIR USE | Genomatica, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| EP-3956462-A1 | OLIVETOL SYNTHASE VARIANTS AND METHODS FOR PRODUCTION OF OLIVETOLIC ACID AND ITS ANALOG COMPOUNDS | Genomatica, Inc. (US) | 2022-02-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274967-A1 | BCAT MODULATION | BCAT2, BCAT1, ABAT | NAA50 1460/4885CHAT 1708/4885EP300 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.